Business
NHS Framework Agreement
NHS Framework Agreement.
About this update from Advanced Medical Solutions Group Plc
[{"type":"text","content":"\n RNS Number : 8301W Advanced Medical Solutions Grp PLC 17 June 2008 \n \n\n\n\n\nFor immediate release \n\n\n17 June 2008\n\n\n\n\n\nRNS REACH\n\nAdvanced Medical Solutions Group plc \n('AMS' or 'the Company')\n\nActivHeal® range included on new NHS framework agreement for\nadvanced woundcare\n\nWinsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that it has been informed by the NHS Supply Chain that its entire ActivHeal® product range has been included on a new framework agreement for the supply of advanced woundcare products to NHS hospital Trusts. The agreement runs from June 2008 to May 2010.\n\nInclusion in this framework agreement continues AMS's direct sales to the NHS, which first purchased ActivHeal® products at the beginning of 2005. \n\nAs of 1st October 2006, the UK Department of Health outsourced the NHS Logistics Authority and part of the NHS Purchasing and Supply Agency. The new contracting entity is the NHS Business Services Authority and the process is administrated by the NHS Supply Chain, now part of DHL Logistics.\n\nThis is the first procurement project of its type in the medical device arena and involved a robust supplier selection process including clinical user groups to assess economic and clinical aspects of companies' products. The evaluation included cost, quality, clinical data, innovation, manufacturing capability, user education and clinical/technical support.\n\nThe ActivHeal® range was rated highly in the assessment reflecting the comprehensive offering by AMS in this product sector. The product range consists of alginate, foam, hydrocolloid, hydrogel and the recently introduced AquaFibre® high absorbancy, clear gelling dressing.\n\nActivHeal® products are offered direct to the NHS as a first line therapy for treating routine wounds and offer substantial savings in woundcare budgets. They complement the use of AMS's new technologies, such as silver alginate, for treating infected or more difficult to heal wounds. These new technologies are sold through strategic partners.\n\nCommenting on this ann...